Results 111 to 120 of about 10,199,072 (234)

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

British Journal of Haematology, Volume 208, Issue 6, Page 2104-2112, June 2026.
Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, Daniel Tuyet Kristensen, Karen Dybkær, Kirsten Grønbæk, Tarec Christoffer El‐Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen, Marianne Tang Severinsen   +11 more
wiley   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

British Journal of Pharmacology, Volume 183, Issue 12, Page 3355-3376, June 2026.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez   +28 more
wiley   +1 more source

Selection of L-asparaginase PEGylation sites.

, 2018
(A) L-Asparaginase tetramer with subunits highlighted with different colors, one active site is represented in red spheres, the pre-selected PEGylation positions in blue spheres, and the distances between mutated residues (A38C and T263C) are shown by ...
Josell Ramirez-Paz (3852553), Virginia A. Rojas-Nieves (5565800), Zhongfang Chen (1288152), Kai Griebenow (23303), Manoj Saxena (2624236), Louis J. Delinois (5565791), Shiru Lin (5565797), Freisa M. Joaquín-Ovalle (5565794)   +7 more
core   +1 more source

L-Asparaginase Encapsulation into Asymmetric Permeable Polymersomes [PDF]

, 2020
This work reports, for the encapsulation of l-asparaginase, an anticancer enzyme into hybrid PMPC25–PDPA70/PEO16–PBO22 asymmetric polymersomes previously developed by our group, with loading capacities with over 800 molecules per vesicle.
Poma, A, Battaglia, G, Bueno, CZ, Duro-Castano, A, Rangel-Yagui, CO, Pessoa, A, Apolinario, AC   +6 more
core  

Untersuchungen zur Asparagin Synthetase-Expression als Surrogatparameter für das Therapieansprechen auf L-Asparaginase und für L-Asparaginase Toxizität

, 2004
L-Asparaginase ist Bestandteil der Therapie der ALL und des NHL. Es katalysiert die Hydrolyse von L-Asparagin . Normale Körperzellen besitzen Asparagin Synthetase (ASYN), die die Synthese des L-Asparagins ermöglicht.
Stern, C. (Claudia)
core   +1 more source

Chemosensitizing effect of apigenin on T-ALL cell therapy

Frontiers in Pharmacology
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with limited therapeutic options and frequent treatment-associated toxicities.
Nigar Huseynova, Züleyha Baran, Rovshan Khalilov, Afat Mammadova, Yusuf Baran   +4 more
doaj   +1 more source

L-asparaginase-antileukemia agent.

JPMA. The Journal of the Pakistan Medical Association, 1977
This paper is an extension of a previous report (Yaqub 1975). Our interest in L-asparaginase is increasing due to the recognition of the fact that it is a best tool against leukemia. In this paper we have tried to discuss (in view of research work, 1973-75) its basic characteristics and its practicability of successfully being used as an antitumour ...
A, Jabbar, M, Yaqub
openaire   +2 more sources

Exploring Taphrina deformans, the Springtime Scourge of Peach

Molecular Plant Pathology, Volume 27, Issue 6, June 2026.
This review integrates current knowledge on host–pathogen interactions, epidemiological processes, resistance mechanisms and peach‐resistant varieties, while critically identifying key knowledge gaps. It provides the first comprehensive, integrative description of the Taphrina deformans life cycle in relation to the annual developmental cycle of the ...
Clotilde Nigon, Morgane Roth, Bénédicte Quilot   +2 more
wiley   +1 more source

Recent progress on the development of nanoparticulate L-asparaginase for enhanced anti-cancer activity

Cancer Nanotechnology
Background L-Asparaginase is a medically important enzyme known to be a chemotherapeutic agent and is often used in multi-agent chemotherapeutic regimens.
Sahand Mazloum-Ravasan, Hamed Hamishehkar   +1 more
doaj   +1 more source

Metabolic Enzyme MeHNL11 Regulates MeCAS1b Transcription for Cyanide Reutilization in Response to Nitrate Deficiency in Cassava

Plant Biotechnology Journal, Volume 24, Issue 6, Page 4121-4135, June 2026.
ABSTRACT Cassava (Manihot esculenta Crantz) exhibits exceptional tolerance to infertile soils and contains abundant cyanogenic glucosides (CGs). Previous research has indicated that CGs can serve as a significant reservoir of organic nitrogen in plants.
Weitao Mai, Ruxue Bao, Xiaocheng Liu, Mengtao Li, Jinling Zhao, Huaifang Zhang, Yuan Yao, Haiyan Wang, Wenquan Wang, Changying Zeng, Xin Chen   +10 more
wiley   +1 more source